Abstract:Background Heart failure (HF) with preserved Ejection Fraction (HFpEF) is common among older adults and is associated with a high burden of morbidity and mortality. Despite its increasing prevalence, the diagnosis of HFpEF remains challenging. Recently, the FDA cleared an echocardiography-based AI HFpEF model that utilizes a 3-dimensional convolutional neural network to detect HFpEF using a single 4-chamber clip from a resting echocardiogram. However, the external validation of this algorithm against clinically adjudicated and confirmed HFpEF is limited. Purpose To evaluate the diagnostic and prognostic performance of the echocardiography-based AI HFpEF model in a cohort of HFpEF patients and matched controls. Methods The study included patients with clinically adjudicated HFpEF based on clinical history, normal ejection fraction (>45%), and evidence of elevated filling pressure by resting (PCWP > 15 mm Hg) or exercise invasive hemodynamics (PCWP > 25 mm Hg) or echocardiogram (E/e' >14). The controls were age, sex, and BMI-matched patients without HF and a normal echocardiogram. The performance of the AI HFpEF model was evaluated using receiver operator curves. In patients with HFpEF, the association of the AI-HFpEF phenotype with elevated resting/exercise PCWP and peak exercise oxygen uptake (VO2peak) was assessed using multivariable logistic and linear regression models adjusting for age, sex, race, BMI, and comorbidities (diabetes, hypertension, kidney disease, atrial fibrillation). Results Of the 166 patients referred for evaluation of HFpEF, 82% had clinically adjudicated HFpEF, and 69.8% had elevated LV filling pressure at rest or exercise. In the matched cohorts of patients with clinically adjudicated HFpEF and matched control individuals (N = 122 each), the AI algorithm-based probability of HFpEF demonstrated good performance in identifying clinically adjudicated and hemodynamically confirmed HFpEF (AUROC: 0.75 for each) that was greater than the widely used H2FpEF score (0.69 and 0.70, Figure). In the HFpEF referral cohort, a higher probability of HFpEF based on the AI-algorithm phenotype was significantly associated with lower VO2peak (b [95% CI] per 5% higher probability: -0.11 [-0.21 to -0.01, P-value: 0.03] and greater odds of elevated PCWP (Odds ratio [95% CI] per 5% higher probability: 1.07 [1.01 – 1.15, P-value: 0.04] at rest or exercise after accounting for other confounders. Based on Youden's index, the AI algorithm-based probability threshold of >0.75 was identified as the optimal cutoff for detecting HFpEF by the AI algorithm, with high sensitivity (0.85) and accuracy (0.74) and, adequate specificity (0.66). Conclusion The echocardiography-based AI HFpEF model demonstrated excellent sensitivity and discrimination in identifying patients with vs. without clinical HFpEF. Furthermore, the AI HFpEF model also had prognostic utility such that individuals with a higher probability of AI-HFpEF phenotype had more severe HFpEF.

AI-driven Classification of Heart Failure Preserved and Reduced Ejection Fraction Patients Using the Total Protein Approach

Abstract 18252: Comparison of an Artificial Intelligence Heart Failure Detection Model and Clinical Prediction Models in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)

Automated Echocardiographic Detection of Heart Failure With Preserved Ejection Fraction Using Artificial Intelligence

The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction

Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy

Artificial intelligence‐assisted automated heart failure detection and classification from electronic health records

Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study

Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF

Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction

Diagnostic and prognostic evaluation of an echocardiography-based artificial intelligence algorithm for detecting HFpEF: a case-control analysis

Quantitative Metabolomics Reveals Heart Failure With Midrange Ejection Fraction as a Distinct Phenotype of Heart Failure

Performance of an automated echocardiographic artificial intelligence model. to detect subclinical heart failure with preserved ejection fraction (HFpEF) in community-dwelling older adults

Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction

Unbiased clustering and molecular characterisation of novel metabolic phenotypes in a heart failure cohort

Abstract 11983: Biomarker Profile of Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction or Reduced Ejection Fraction: Insights From the ARISTOTLE Trial

Targeted metabolomic analysis of serum amino acids in heart failure patients

Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum

Deciphering the Protein, Modular Connections and Precision Medicine for Heart Failure With Preserved Ejection Fraction and Hypertension Based on TMT Quantitative Proteomics and Molecular Docking

Clinical Utility Of An AI-Based Model For Detection Of Heart Failure With Preserved Ejection Fraction Using Decision Curve Analysis